Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $42.64 Average Target Price from Brokerages

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has received a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $42.6429.

VRDN has been the topic of a number of research reports. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $40.00 price target on shares of Viridian Therapeutics in a research note on Thursday, November 6th. Royal Bank Of Canada upped their target price on Viridian Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Truist Financial cut their price target on Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $42.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, February 4th. Finally, BTIG Research restated a “buy” rating and issued a $61.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, November 4th.

Insider Buying and Selling at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 2,272 shares of the company’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total value of $70,795.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.58% of the company’s stock.

Institutional Trading of Viridian Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd acquired a new position in shares of Viridian Therapeutics during the 3rd quarter valued at about $35,000. ANTIPODES PARTNERS Ltd acquired a new position in Viridian Therapeutics during the fourth quarter valued at approximately $36,000. Farther Finance Advisors LLC grew its holdings in Viridian Therapeutics by 332.1% during the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after purchasing an additional 1,491 shares during the last quarter. Bessemer Group Inc. raised its position in shares of Viridian Therapeutics by 947.7% in the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after purchasing an additional 1,886 shares during the period. Finally, Larson Financial Group LLC acquired a new stake in shares of Viridian Therapeutics in the third quarter worth $52,000.

Viridian Therapeutics Stock Performance

Shares of VRDN opened at $28.10 on Tuesday. The company has a market capitalization of $2.68 billion, a PE ratio of -9.30 and a beta of 0.98. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.28 and a current ratio of 11.28. The company’s 50 day moving average price is $31.46 and its 200 day moving average price is $25.91. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $34.29.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.